Anthropic using Claude to discover a novel CRISPR-like enzyme system in bacteriophages marks the pivot from chat wrappers to automated biotech IP. With inference costs dropping 40% per model cycle, basic text generation cannot justify multi-trillion dollar valuations. Committing $1B to safety red-teaming is regulatory PR while Anthropic builds an automated bio-discovery engine. Finding uncharacterized genomic structures proves frontier labs are moving into synthetic biology and drug discovery, where proprietary patents create actual defensive moats against open-weight models. https://t.co/soeBRGb6Z4